Results 151 to 160 of about 2,330 (177)

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Simon Y Graeber, Lutz Naehrlich, M Stahl   +2 more
exaly  

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine, 2022
Marcus A Mall, Silvia Gärtner, Alexander Moeller   +2 more
exaly  

Elexacaftor‐tezacaftor‐ivacaftor overdose in an adolescent female with cystic fibrosis

Pediatric Pulmonology, 2022
Benjamin C. Lyman, Jessica Seay, Casey Contreary, Adrienne P. Savant, Mary Lynn Dell, George C. Hescock   +5 more
openaire   +2 more sources

Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers

Pediatric Pulmonology, 2023
Christina J Bathgate, Emily F Muther, Anna M Georgiopoulos   +2 more
exaly  

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Simon Y Graeber, M Stahl, Martha Dohna
exaly  

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

Journal of Cystic Fibrosis, 2022
Max C Petersen
exaly  

Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal
Peter G. Middleton, Nicholas J. Simmonds
openaire   +2 more sources

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul Mcnally, Michael Williamson, Edward Mckone   +2 more
exaly  

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul Mcnally, Jane C Davies
exaly  

ePS5.08 The effects on systemic inflammation of elexacaftor/tezacaftor/ivacaftor

Journal of Cystic Fibrosis, 2022
N. Robinson, G. Hardisty, R.D. Gray
openaire   +1 more source